jynarque: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441	NDA	Otsuka America Pharmaceutical, Inc.	59148-079-28	4 BLISTER PACK in 1 CARTON (59148-079-28) / 1 KIT in 1 BLISTER PACK (59148-079-07)	2020-01-13
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441	NDA	Otsuka America Pharmaceutical, Inc.	59148-080-28	4 BLISTER PACK in 1 CARTON (59148-080-28) / 1 KIT in 1 BLISTER PACK (59148-080-07)	2020-01-13
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441	NDA	Otsuka America Pharmaceutical, Inc.	59148-082-13	1 BOTTLE in 1 CARTON (59148-082-13) / 30 TABLET in 1 BOTTLE	2018-04-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 31, 2025

Introduction

Jynarque (taflsense), developed by Reddy’s Laboratories and marketed by companies like Otsuka Pharmaceutical, is a pioneering medication approved by the U.S. Food and Drug Administration (FDA) for treating autosomal dominant polycystic kidney disease (ADPKD). As a branded pharmaceutical, Jynarque's supply chain comprises multiple stakeholders, including active pharmaceutical ingredient (API) manufacturers, formulation plants, packaging units, and distribution channels. Understanding its suppliers across this spectrum is critical for stakeholders considering supply chain stability, procurement strategies, or market entry. This article offers a comprehensive overview of the key suppliers and manufacturing entities involved in Jynarque's production, emphasizing their roles, geographic locations, and influence on the drug’s availability.

Overview of Jynarque Manufacturing and Supply Chain

Jynarque’s supply chain encompasses several stages—from raw material sourcing and API synthesis to formulation, packaging, and distribution. Ensuring a secure and compliant supply chain is vital given the drug's role in managing ADPKD, a progressive and often debilitating condition. Key suppliers at various stages include:

API Manufacturers
Formulation and Filling Facilities
Packaging and Labeling Providers
Distribution Channels and Logistics Partners

Below, we detail the landscape of each component, drawing on industry reports, patent filings, and market analyses.

Active Pharmaceutical Ingredient (API) Suppliers

The foundation of Jynarque's supply chain hinges on the procurement of high-quality taflsense, the active pharmaceutical ingredient. The API's synthesis involves complex chemical processes requiring specialized expertise and rigorous quality controls.

Major API Manufacturers

Despite limited public disclosures, industry dynamics and regulatory filings suggest several key players involved in taflsense API production:

Reddy’s Laboratories: As the originator of Jynarque, Reddy’s likely maintains in-house API manufacturing capabilities or contractual arrangements with dedicated API producers. Reddy’s has a global footprint with API manufacturing facilities located predominantly in India, which supplies both the domestic Indian market and international exports.
Contract Manufacturing Organizations (CMOs):
Several global CMOs capable of synthesizing complex APIs have been identified as potential partners. These include:
- Jubilant Life Sciences (India):Known for substantial API manufacturing, especially for complex molecules, Jubilant may serve as a supplier or contract partner, given its extensive capabilities in chemical synthesis.
- Hetero Labs (India): Hetero possesses robust API production platforms and has historically collaborated with international pharma companies for complex APIs, possibly including taflsense.
- Dishman Pharmaceuticals & Chemicals: With a focus on fine chemicals and APIs, Dishman operates several facilities in India capable of high-grade API synthesis.
European and U.S.-Based API Producers:
Limited evidence suggests smaller, specialized facilities in Europe and North America could be involved, mainly serving niche markets or supplying regulatory imports.

Regulatory and Quality Considerations

Manufacturers supplying APIs for Jynarque must adhere to Good Manufacturing Practices (GMP) and demonstrate consistent quality for regulatory approval. Suppliers cited in Regulatory filings or sourced from the FDA's Drug Master Files (DMFs) bolster these claims.

Formulation, Filling, and Packaging Suppliers

Once the API is produced, it is sent to formulation plants where the medication is encapsulated, filled, and packaged for distribution.

Key Formulation and Filling Facilities

Otsuka’s Manufacturing Sites:
Otsuka Pharmaceutical, a global leader in innovative medicines, likely owns or oversees facilities responsible for final formulation, fill-finish, and packaging. These plants are typically located in countries with strong pharmaceutical manufacturing infrastructure, including the U.S., Japan, and India.
Contract Manufacturing Organizations (CMOs):
Reddy’s Laboratories and third-party CMOs such as Catalent, Patheon (Thermo Fisher Scientific), and Siegfried AG often handle drug formulation and packaging for specialty drugs like Jynarque.
- Catalent: A prominent contract manufacturer with extensive capability in fill-finish processes, with facilities in the U.S., Europe, and Asia.
- Patheon: Owned by Thermo Fisher Scientific, known for large-scale injectable and capsule manufacturing.
- Siegfried AG: Swiss-based CDMO with specialty expertise in complex formulations.

Packaging and Labeling

Providers like Amcor and Gerresheimer, specializing in pharmaceutical packaging, are likely involved in supplying primary and secondary packaging components for Jynarque, ensuring compliance with safety and branding standards.

Distribution and Logistics

Distribution is handled through a combination of:

Otsuka’s Global Distribution Network:
Otsuka typically manages or partners with specialized logistics firms to ensure cold chain and secure supply, especially given Jynarque’s significance in managing ADPKD.
Third-party Logistics (3PL) Providers:
Companies like DHL Supply Chain, FedEx Pharma, and UPS Healthcare provide temperature-sensitive shipping, customs clearance, and warehousing.
Regional Distribution Partners:
In various countries, local distributors and pharmacies receive supplies through regional partnerships, ensuring broad patient access.

Emerging Trends: Supply Chain Resilience and Diversification

The COVID-19 pandemic emphasized the importance of diversification among suppliers for essential medicines like Jynarque. Reddy’s and Otsuka have been working to mitigate supply chain disruptions by engaging multiple API sources and establishing redundancy in manufacturing sites.

Similarly, India and emerging markets are becoming vital hubs for API manufacturing due to cost advantages and capacity expansion, although regulatory compliance remains paramount.

Regulatory and Patent Landscape

The patent protection for taflsense influences supplier choices and licensing. Once patent exclusivity diminishes, generic manufacturers may enter the market, altering the supplier landscape:

Patent Status:
As of recent filings, Jynarque retains patent protection in key markets, limiting suppliers to authorized manufacturers.
Biosimilar and Generic Competition:
Pending biosimilar or generic entries could expand supplier bases, especially in markets outside FDA jurisdiction.

Conclusion

The supply chain for Jynarque is characterized by integrated manufacturing processes with primary involvement from Reddy’s Laboratories, complemented by partnerships with contract manufacturers, API suppliers, and logistics providers. India remains a central hub for API production, leveraging manufacturing capacity and cost advantages, while formulation and packaging are managed across global facilities—often through CMOs with specialized expertise.

Ensuring continued supply stability depends on managing geopolitical risks, regulatory compliance, and diversification efforts, especially as patent exclusivity evolves and market dynamics shift.

Key Takeaways

Reddy’s Laboratories is the primary driver behind Jynarque’s API and final formulation, with multiple API suppliers likely involved, predominantly based in India.
CMOs like Catalent and Patheon play crucial roles in formulation, fill-finish, and packaging, enabling scalable production and distribution.
Logistics partners specializing in cold chain management ensure Jynarque’s timely and safe delivery across global markets.
Diversification of suppliers and manufacturing sites enhances supply chain resilience amid geopolitical and regulatory uncertainties.
Monitoring patent expirations and regulatory developments is essential, as emerging generic and biosimilar competitors could change supplier dynamics.

FAQs

Q1: Who are the main API suppliers for Jynarque?
A: Reddy’s Laboratories is likely the primary API manufacturer, possibly supplemented by Indian CMOs such as Jubilant Life Sciences and Hetero Labs, which possess the technical capacity for complex API synthesis.

Q2: Are there any alternative sources for Jynarque’s manufacturing?
A: While Reddy’s is the core manufacturer, the global trend towards supply chain diversification includes other Indian and possibly European or U.S.-based CMOs ready to support manufacturing, pending regulatory approval.

Q3: How is Jynarque packaged and distributed?
A: Packaging and distribution are managed through a combination of Otsuka’s global facilities and third-party CMOs, with logistics providers ensuring temperature-sensitive storage and shipment.

Q4: What are the risks in Jynarque’s supply chain?
A: Heavy reliance on Indian API producers and specific formulation facilities poses risks related to geopolitical disruptions, regulatory changes, and capacity constraints.

Q5: Will generic versions impact Jynarque’s suppliers?
A: Patent protections could delay generic entrants; however, once patents expire, a surge of generic manufacturers will likely enter the market, expanding supplier options and potentially reducing costs.

References

U.S. FDA Drug Approval Package for Jynarque (TAFLISENSE), FDA.gov
Market analysis reports on API manufacturing and CDMOs, IndustryWeek
Patent filings and regulatory submissions, USPTO and EMA databases
Industry news on contract manufacturing capacity and supply chain diversification, Chemical & Engineering News

Suppliers and packagers for jynarque

jynarque

Suppliers for the Pharmaceutical Drug: Jynarque